Developing Diagnostics for Personalized Medicine
By developing the molecular testing products necessary to target the right preventive and treatment interventions to the right patients at the right times, diagnostics companies provide the infrastructure necessary to deliver personalized medicine.
Since 2004, the industry has developed nearly 100,000 molecular testing products, many of which have helped make personalized medicine what it is today. As STAT reported after last year’s Annual Personalized Medicine Conference, diagnostics companies often prioritize the development of molecular testing products despite spotty health insurance coverage that limits their ability to recoup research and development costs.
During the discussion titled “Developing Diagnostics for Personalized Medicine,” Kimberly Popovits, who helped create and lead one of the most successful diagnostics companies in the history of personalized medicine for 17 years as the CEO of Genomic Health, will moderate a discussion with four diagnostics company executives to examine the opportunities and obstacles facing the industry in increasingly challenging economic and political environments.
The discussion promises to inform policymakers, industry advocates, and business leaders about the steps they can take to encourage the continued growth of a diagnostics sector whose products are responsible for guiding no less than 70 percent of the medical decisions that affect how the United States cares for ailing patients.